Search

Xenon Pharmaceuticals Inc

Nyitva

SzektorEgészségügy

41.62 2.16

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

40.54

Maximum

41.77

Fő mutatók

By Trading Economics

Bevétel

301K

-110M

Egy részvényre jutó nyereség

-1.11

Munkavállalók

358

EBITDA

-9.3M

-120M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+77.64% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

274M

3.9B

Előző nyitás

39.46

Előző zárás

41.62

Xenon Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. nov. 10. 20:51 UTC

Social Media
News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million, and advances its drug pipeline.

2026. nov. 9. 23:02 UTC

News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million loss, with operating expenses rising to $120.1 million.

2026. nov. 6. 21:03 UTC

Xenon Pharmaceuticals Inc. is trading higher, diverging from a downward shift in the broader market despite recent upward momentum in prior sessions.

2026. nov. 5. 22:11 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-market hours amid a broader market decline.

2026. nov. 4. 21:07 UTC

Xenon Pharmaceuticals Inc. gained significantly during Wednesday's trading, maintaining strong upward momentum and finishing above its 20-day moving average since Tuesday's close.

2026. nov. 3. 21:07 UTC

Xenon Pharmaceuticals Inc. is trading higher, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

2026. nov. 2. 20:52 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, positioned above its 20-day moving average and near the upper end of its one-month range.

2026. okt. 30. 20:08 UTC

Social Media
News

Stifel sets a price target of $86 for Xenon Pharmaceuticals and maintains a "Buy" rating, citing the company's developing pipeline for epilepsy treatments.

2026. okt. 29. 20:04 UTC

News
Social Media

Xenon Pharmaceuticals reports positive Phase 1 results for XEN1701 and XEN1120, supporting progression to Phase 2 studies in acute pain, presented at IASP 2026.

2026. okt. 28. 19:36 UTC

Xenon Pharmaceuticals Inc. is seeing a modest advance on Wednesday, marking three consecutive sessions of gains despite a slight pullback from its mid-morning peak.

2026. okt. 27. 20:07 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, settling in the middle of its one-month trading range after a brief dip earlier in the day.

2026. okt. 23. 20:01 UTC

Xenon Pharmaceuticals Inc shares are declining, reversing recent gains and reflecting a downward shift since Thursday's close.

2026. okt. 22. 19:41 UTC

Xenon Pharmaceuticals Inc is experiencing higher price movement, supported by significant gains in the Biotechnology sub-sector, trading within the middle of its one-month range.

2026. okt. 21. 23:46 UTC

Xenon Pharmaceuticals Inc shares are trading lower in after-market hours, following a notable drop from an earlier high amid broader market weakness.

2026. okt. 20. 20:02 UTC

Xenon Pharmaceuticals Inc shares are advancing, having reached a peak earlier in the session, marking a significant increase within its one-month trading range.

2026. okt. 19. 20:02 UTC

Xenon Pharmaceuticals Inc shares are gaining amid a broader market trend of higher daily closes since Friday's close.

2026. okt. 16. 20:02 UTC

Xenon Pharmaceuticals Inc shares are declining sharply, continuing a downward trend since Thursday and remaining significantly below their 20-day moving average.

2026. okt. 15. 20:03 UTC

Xenon Pharmaceuticals Inc shares are advancing, influenced by a significant upward movement in the Biotechnology sub-sector, despite earlier pulling back from a session high.

2026. okt. 14. 19:21 UTC

Xenon Pharmaceuticals Inc shares fell significantly, continuing a downward trend with three consecutive sessions of losses and remaining below its 20-day moving average.

2026. okt. 13. 20:01 UTC

Xenon Pharmaceuticals Inc shares fell, breaking a trend of higher daily closes, contrasting with recent upward momentum since Monday's close.

2026. okt. 9. 20:06 UTC

Xenon Pharmaceuticals Inc shares are modestly higher, peaking in early afternoon trading.

2026. okt. 8. 19:15 UTC

Xenon Pharmaceuticals Inc shares are declining, marking five consecutive sessions lower, and remain significantly below their 20-day moving average amid ongoing market weakness.

2026. okt. 6. 20:02 UTC

Xenon Pharmaceuticals Inc shares fell sharply, continuing a downward trend with unusually high volume and remaining below the 20-day moving average.

2026. okt. 5. 20:06 UTC

News

Xenon Pharmaceuticals Inc shares are declining, continuing a trend from Friday's close, despite an earlier rebound from a session low.

2026. okt. 2. 21:01 UTC

News

Xenon Pharmaceuticals Inc announced equity inducement grants to new employees, with after-market trading showing a slight gain since Friday's close.

2026. okt. 1. 23:55 UTC

Xenon Pharmaceuticals Inc declined in after-market trading, moving lower since Thursday's close and remaining significantly below its 20-day moving average.

2026. szept. 30. 20:07 UTC

Xenon Pharmaceuticals Inc. shares fell, closing lower than Tuesday's close after an early drop, remaining below its 20-day moving average.

2026. szept. 29. 20:01 UTC

Xenon Pharmaceuticals Inc is advancing today with increased trading volume, recovering from earlier losses to reach a peak in late morning.

2026. szept. 28. 23:55 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-hours, shifting from a slight gain to a more substantial loss since Monday's close, remaining below its 20-day moving average.

2026. szept. 25. 20:01 UTC

Xenon Pharmaceuticals Inc shares fell sharply, pressured by broader biotechnology sector weakness, and are nearly 3% below Thursday's close.

Társak összehasonlítása

Árváltozás

Xenon Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

77.64% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 69.583 USD  77.64%

Magas 90 USD

Alacsony 46 USD

16 Wall Street elemző 12 hónapos célárain alapulva a(z)Xenon Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

16 ratings

15

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat